First Wave BioPharma goes public at $6M

First Wave BioPharma, a company specializing in treating gastrointestinal disease, has priced its public offering at $6 million.

Advertisement

The initial public offering includes about 3.4 million shares of its common stock priced at $1.745 per share and is expected to close on Oct. 11. H.C. Wainright & Co. is acting as the exclusive placement agent for the offering, according to the Oct. 6 First Wave news release provided to Becker’s.

The company plans to use the capital to make the final payment owed to former stockholders of First Wave and for general working capital. 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.